Brief: Decibel Therapeutics Announces Approval Of Clinical Trial Application To Initiate Clinical Development Of Lead Gene Therapy Candidate, Db-OTO
12/05/2023 14:50
May 12 (Reuters) - Decibel Therapeutics Inc DBTX.O :
* DECIBEL THERAPEUTICS ANNOUNCES APPROVAL OF CLINICAL TRIAL
APPLICATION BY THE SPANISH AGENCY OF MEDICINES AND MEDICAL
DEVICES (AEMPS) TO INITIATE CLINICAL DEVELOPMENT OF LEAD GENE
THERAPY CANDIDATE DB-OTO
* DECIBEL THERAPEUTICS-EXPECTS REPORTING INITIAL SAFETY,
TOLERABILITY DATA & PRELIMINARY EFFICACY DATA FROM FIRST
PATIENTS IN PHASE 1/2 CLINICAL TRIAL IN Q1 2024
Source text for Eikon: ID:nGNX4xZ5RW
Further company coverage: DBTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Decibel Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Domo, BlackBerry, Rite Aid
U.S. STOCKS ON THE MOVE-Decibel Therapeutics, Affirm Holdings, Medtronic
Decibel rises on FDA's 'fast-track' tag for hearing-loss therapy
Brief: Decibel Therapeutics Says US Food And Drug Administration Had Granted Fast Track Designation For DB-OTO
Decibel Therapeutics Inc reports results for the quarter ended in June - Earnings Summary